MILAN — Liver transplantation improves survival in patients with acute-on-chronic liver failure (ACLF), according to interim clinical outcomes of the large, international CHANCE study. To date, the ...

Safety data from Phase 1 on healthy volunteers and initial efficacy signals from ex-vivo functional assays expected by year-end 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich ...

Under this research collaboration, EVerZom will contribute exosome expertise with associated bioproduction platform, while GENFIT will spearhead preclinical evaluation of EViv Lille (France), ...

Please provide your email address to receive an email when new articles are posted on . Promethera Biosciences announced the initiation of a phase 2b clinical trial to evaluate the safety and efficacy ...

Systemic inflammation and portal hypertension are key predictors of acute-on-chronic liver failure (ACLF) in the 3 months after a hospital stay for acute decompensated cirrhosis and also of death ...

Please provide your email address to receive an email when new articles are posted on . Delayed antibiotic therapy increased the odds for death in patients with acute-on-chronic liver failure (ACLF).

Acute-on-chronic liver failure (ACLF) is a critical and often fatal syndrome characterized by a sudden exacerbation of chronic liver disease, leading to multi-organ failure and high short-term ...

For patients with chronic liver disease, the onset of acute-on-chronic liver failure (ACLF) instantly alters the transplant question from "if" to "when." Between 60 and 70% of patients with ACLF die ...

People with severe acute-on-chronic liver failure (ACLF) were more likely to die than those without ACLF while waiting for a liver transplant, despite having similar survival rates if they did get a ...

A poster on the Effect of VS-01 on systemic inflammation and liver injury in a rat model of endotoxemia will also be presented by GENFIT. While VS-01 has been discontinued in ACLF, pre-clinical ...